1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,876 | 0,919 | 11:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 52,82 | -0,15 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 270,80 | -1,53 % | Genmab: Nach wie vor ein schwacher Ausblick | Genmab überrascht Quartal für Quartal. Viermal infolge mindestens 29 % mehr Gewinn als erwartet. Schlafen die Prognostiker Den vollständigen Artikel lesen ... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,832 | -3,57 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| VERICEL | 33,000 | +3,12 % | Vericel Corporation: Vericel Reports Third Quarter 2025 Financial Results | Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow... ► Artikel lesen | |
| MOLECULIN BIOTECH | 5,040 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026 | Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,020 | +5,25 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,838 | +3,96 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,326 | +0,93 % | MustGrow Biologics Corp.: MustGrow Reports Significant U.S. Potato Yield and Economic Performance in Large Scale Field Trials Utilizing TerraSante | Mustard-derived organic TerraSanteTM focuses on crop yields, soil and soil microbiome health, and nutrient/water use efficiencies;Large scale field trial showed 2 ton per acre yield increase with larger... ► Artikel lesen | |
| AKEBIA | 1,488 | +4,94 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| REGENXBIO | 11,000 | 0,00 % | REGENXBIO Inc.: REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights | RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026
Pivotal trial enrollment... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,250 | +1,40 % | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD | CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,350 | 0,00 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | - City of Hope to Evaluate PEDMARK- for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors - - Initiation of Study Reflects Growing Clinical Interest in Addressing... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | AbbVie wins $56M royalty award from Revance in Botox patent infringement case | ||
| CORVUS PHARMACEUTICALS | 7,160 | 0,00 % | Corvus Pharmaceuticals stock awaits key January 2026 trial data | ||
| CARTESIAN THERAPEUTICS | 6,850 | +9,60 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |
Das Unternehmen SYNTHAVERSE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,006 (-0,67 %) liegt der Kurs bei 0,883 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.